Opportunity Information: Apply for W81XWH 14 DMRDP MID ARA
Apply for W81XWH 14 DMRDP MID ARA
- The Dept. of the Army USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Military Infectious Diseases Applied Research Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420 Military Medical Research and Development.
- This funding opportunity was created on Oct 9, 2013 and posted on Apr 24, 2013.
- Applicants must submit their applications by Oct 17, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $11,100,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The DOD Military Infectious Diseases Applied Research Award (MID ARA) under the Defense Medical Research and Development Program is a FY14 funding opportunity aimed at reducing illness and death from combat-related or trauma-induced wound infections. The program is explicitly product- and translation-oriented: proposed work is expected to push a tangible medical product, tool, or approach closer to human testing rather than explore basic biology for its own sake. Projects should be framed as applied research with a clear path toward practical use in military and trauma care settings, especially where infections complicate wound healing and recovery.
Applications must directly address at least one of three required focus areas centered on wound infections. First, the program seeks new methods for rapid, multi-pathogen and/or multi-phenotype detection of multidrug-resistant organisms (MDROs) and other hospital-associated pathogens, including tools that can quickly characterize antimicrobial resistance patterns in a clinically useful way. Second, it supports development of assays that measure host immune response biomarkers that can help diagnose infection or predict prognosis, tied to meaningful clinical outcomes that inform wound management decisions (for example, guiding timing of wound closure or determining appropriate antibiotic duration for complications like osteomyelitis). Third, it funds development and preclinical testing of novel therapeutics or prophylactics for wound infection and biofilms, including new chemotypes and materials as well as biologics; the announcement explicitly encourages innovative modalities such as chelators, antibodies, phage, antimicrobial peptides, quorum-sensing inhibitors, and host-directed immunoaugmentation approaches.
The program sets clear priorities across all focus areas. Preference is given to approaches that tackle difficult, clinically relevant pathogens common in military and trauma-associated infections, especially MDROs such as Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA). Invasive fungal (mold) pathogens are also highlighted as priority threats. In addition, the announcement signals a strong preference for work that moves toward topical treatments for prevention and management of wound infection, reflecting the operational need for localized, practical interventions that can be deployed in austere or high-risk environments.
In terms of project maturity, MID ARA is designed to fund studies that bridge the gap between promising concepts and readiness for human testing. Supported activities include hypothesis-driven proof-of-concept work in vitro and/or in vivo, refinement and feasibility testing of emerging technologies, maturation and down-selection of candidate products (including drugs, biologics or vaccine constructs, and devices or systems), and preclinical safety or toxicity packages sufficient to support regulatory submissions such as an Investigational New Drug (IND) or Investigational Device Exemption (IDE). While studies may include human subjects, funds cannot be used to run clinical trials. The opportunity uses a specific definition of a clinical trial as prospective enrollment where an intervention is tested in humans for measurable outcomes related to safety, effectiveness, or efficacy; proposals must avoid crossing that line.
The solicitation also spells out what not to submit. Projects focused on fundamental basic research are not eligible, and applications that rely on high-throughput drug screening and/or in silico modeling are explicitly discouraged for this mechanism. In practical terms, applicants need to show they are beyond early discovery: preliminary data is required, and proposals are expected to present a well-formulated, testable hypothesis supported by a solid scientific rationale and a critical analysis of the existing literature. Competitive applications should read like a focused development plan with realistic milestones that move an intervention, diagnostic, or decision-support approach toward preclinical readiness and eventual human evaluation.
Collaboration is built into the mechanism through an optional Partnering Principal Investigator structure that allows up to three PIs, each receiving a separate award. One PI is designated as the Initiating PI, with the others as Partnering PIs, and the proposal must make it clear that each investigator contributes substantial intellectual leadership and complementary expertise. Multidisciplinary and multi-organizational collaborations are allowed, but participating institutions are expected to proactively resolve intellectual property and material transfer issues so they do not become barriers to completion.
Administratively, this opportunity was offered by the Department of the Army (USAMRAA) under Funding Opportunity Number W81XWH-14-DMRDP-MID-ARA and CFDA 12.420 (Military Medical Research and Development). It was open to essentially any applicant organization type (unrestricted eligibility), did not require cost sharing, and planned to make about five awards from an estimated total funding pool of $11.1 million. The funding instrument type is listed as grant/cooperative agreement under the science and technology research and development category. For applicants needing access help, the announcement directs inquiries to the CDMRP Help Desk at 301-682-5507.
FAQs: DOD Military Infectious Diseases Applied Research Award (MID ARA) (FY14)
What is the MID ARA funding opportunity?
The DOD Military Infectious Diseases Applied Research Award (MID ARA) is a FY14 funding opportunity under the Defense Medical Research and Development Program focused on reducing illness and death from combat-related or trauma-induced wound infections.
What is the overall goal of the program?
The program is designed to advance practical, translation-oriented solutions for wound infection challenges in military and trauma care settings. Proposed work is expected to move a tangible medical product, tool, or approach closer to human testing rather than focus on basic biology for its own sake.
Is this opportunity focused on basic research or applied research?
It is explicitly applied research and product/translation-oriented. Projects focused on fundamental basic research are not eligible for this mechanism.
What types of projects are a good fit for MID ARA?
Projects should read like focused development plans that use preliminary data and a testable, well-supported hypothesis to move an intervention, diagnostic, or decision-support approach toward preclinical readiness and eventual human evaluation.
What are the required focus areas applicants must address?
Applications must directly address at least one of three required focus areas centered on wound infections: (1) rapid multi-pathogen and/or multi-phenotype detection of MDROs and other hospital-associated pathogens, including rapid antimicrobial resistance characterization; (2) host immune response biomarker assays tied to meaningful clinical outcomes to inform wound management decisions; or (3) development and preclinical testing of novel therapeutics or prophylactics for wound infection and biofilms.
What does the program mean by rapid detection in the first focus area?
The first focus area calls for new methods that can rapidly detect multiple pathogens and/or phenotypes and quickly characterize antimicrobial resistance patterns in a clinically useful way, particularly for multidrug-resistant organisms (MDROs) and hospital-associated pathogens relevant to wound infections.
What kinds of biomarker projects are supported under the second focus area?
The second focus area supports assays that measure host immune response biomarkers that can help diagnose infection or predict prognosis, and that are tied to meaningful clinical outcomes that inform wound management decisions (for example, guiding timing of wound closure or helping determine appropriate antibiotic duration for complications such as osteomyelitis).
What kinds of therapeutics or prophylactics are supported under the third focus area?
The third focus area funds development and preclinical testing of novel therapeutics or prophylactics for wound infection and biofilms, including new chemotypes, materials, and biologics. The solicitation explicitly encourages innovative modalities such as chelators, antibodies, phage, antimicrobial peptides, quorum-sensing inhibitors, and host-directed immunoaugmentation approaches.
Are there specific pathogens the program prioritizes?
Yes. Preference is given to approaches that address difficult, clinically relevant pathogens common in military and trauma-associated infections, especially MDROs such as Acinetobacter baumannii, Pseudomonas aeruginosa, extended-spectrum beta-lactamase producing Enterobacteriaceae (including Escherichia coli and Klebsiella pneumoniae), and methicillin-resistant Staphylococcus aureus (MRSA). Invasive fungal (mold) pathogens are also highlighted as priority threats.
Does the program prefer topical approaches?
Yes. The announcement signals a strong preference for work moving toward topical treatments for prevention and management of wound infection, reflecting the need for localized, practical interventions deployable in austere or high-risk environments.
What stage of maturity should a project be at to be competitive?
MID ARA is intended to bridge the gap between promising concepts and readiness for human testing. Applicants are expected to be beyond early discovery and must include preliminary data, a well-formulated testable hypothesis, a solid scientific rationale, and a critical analysis of the existing literature.
What types of activities can MID ARA funds support?
Supported activities include hypothesis-driven proof-of-concept work in vitro and/or in vivo, refinement and feasibility testing of emerging technologies, maturation and down-selection of candidate products (including drugs, biologics or vaccine constructs, and devices or systems), and preclinical safety/toxicity packages sufficient to support regulatory submissions such as an IND or IDE.
Can the award support work aimed at preparing for an IND or IDE?
Yes. The opportunity allows preclinical safety or toxicity work that is sufficient to support regulatory submissions such as an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE).
Are human subjects allowed under this mechanism?
Studies may include human subjects, but the funds cannot be used to run clinical trials under this opportunity.
Does this opportunity allow clinical trials?
No. Funds cannot be used to conduct clinical trials.
How does this solicitation define a clinical trial?
A clinical trial is defined as prospective enrollment where an intervention is tested in humans for measurable outcomes related to safety, effectiveness, or efficacy. Proposals must avoid crossing into that type of study.
What kinds of approaches are discouraged or not allowed?
Projects focused on fundamental basic research are not eligible. Applications that rely on high-throughput drug screening and/or in silico modeling are explicitly discouraged for this mechanism.
Is preliminary data required?
Yes. The solicitation states that preliminary data is required and that applicants should demonstrate they are beyond early discovery.
What does the program expect in terms of scientific rationale and literature support?
Proposals are expected to present a well-formulated, testable hypothesis supported by a solid scientific rationale and a critical analysis of the existing literature.
Is there an option for multiple principal investigators?
Yes. The mechanism includes an optional Partnering Principal Investigator structure that allows up to three PIs.
How does the Partnering PI structure work?
One PI is designated as the Initiating PI and the others are Partnering PIs. Each PI receives a separate award, and the application must clearly demonstrate that each investigator provides substantial intellectual leadership and complementary expertise.
Are multidisciplinary or multi-organization collaborations allowed?
Yes. Multidisciplinary and multi-organizational collaborations are allowed under this opportunity.
What does the solicitation say about intellectual property (IP) and material transfer issues in collaborations?
Participating institutions are expected to proactively resolve intellectual property and material transfer issues so they do not become barriers to completing the project.
Who is the issuing agency for this opportunity?
The opportunity was offered by the Department of the Army (USAMRAA) under the Defense Medical Research and Development Program.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is W81XWH-14-DMRDP-MID-ARA.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 12.420 (Military Medical Research and Development).
What types of applicants are eligible to apply?
Eligibility was described as unrestricted, meaning essentially any applicant organization type could apply.
Is cost sharing required?
No. The opportunity did not require cost sharing.
How many awards were expected to be made and what was the approximate funding pool?
The solicitation planned to make about five awards from an estimated total funding pool of $11.1 million.
What is the funding instrument type?
The funding instrument type is listed as grant/cooperative agreement under the science and technology research and development category.
Who should applicants contact for access or submission help?
The announcement directs applicants needing access help to the CDMRP Help Desk at 301-682-5507.
Browse more opportunities from the same agency: Dept. of the Army USAMRAA
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Programs for North Korea
Previous opportunity: CONSERVATION EASEMENT BOUNDARY SURVEY ASSISTANCE
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 14 DMRDP MID ARA
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 14 DMRDP MID ARA) also looked into and applied for these:
| Funding Opportunity |
|---|
| Sea Otter Surveys and Response to Strandings Apply for F13AS00156 Funding Number: F13AS00156 Agency: Fish and Wildlife Service Category: Science and Technology and other Research and Development Funding Amount: $40,000 |
| DoD Bone Marrow Failure Idea Development Award Apply for W81XWH 13 BMFRP IDA Funding Number: W81XWH 13 BMFRP IDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Proactive Decision Support Apply for 13 SN 0016 Funding Number: 13 SN 0016 Agency: Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Engineering Research Centers Apply for 13 560 Funding Number: 13 560 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Ovarian Cancer Pilot Award Apply for W81XWH 13 OCRP PA Funding Number: W81XWH 13 OCRP PA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Ovarian Cancer Teal Innovator Award Apply for W81XWH 13 OCRP TIA Funding Number: W81XWH 13 OCRP TIA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Ovarian Cancer Academy Award Early Career Investigator Apply for W81XWH 13 OCRP OCA Funding Number: W81XWH 13 OCRP OCA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Gas Turbine Upgrades for Reduced Total Ownership Cost (TOC) and Improved Ship Impact Apply for ONRBAA13 013 Funding Number: ONRBAA13 013 Agency: Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cooperative Ecosystem Studies Unit, Great Lakes Northern Forests CESU Apply for G13AS00040 Funding Number: G13AS00040 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ROSES 2013 Heliophysics Supporting Research Apply for NNH13ZDA001N HSR Funding Number: NNH13ZDA001N HSR Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ROSES 2013 Astrophysics Theory Program Apply for NNH13ZDA001N ATP Funding Number: NNH13ZDA001N ATP Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ROSES 2013 Heliophysics Infrastructure and Data Environment Enhancements Apply for NNH13ZDA001N HIDEE Funding Number: NNH13ZDA001N HIDEE Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ROSES 2013 The GLOBE Implementation Office Apply for NNH13ZDA001N GLOBE Funding Number: NNH13ZDA001N GLOBE Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Cooperative Ecosystem Studies Unit, Colorado Plateau CESU Apply for G13AS00042 Funding Number: G13AS00042 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Physics Frontiers Centers Apply for 13 559 Funding Number: 13 559 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $5,000,000 |
| Arrays at Commercial Timescales (ACT) Apply for DARPA BAA 13 26 Funding Number: DARPA BAA 13 26 Agency: DARPA Microsystems Technology Office Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ROSES 2013 Carbon Monitoring System Continuing Prototype Product Development, Research, and Scoping Apply for NNH13ZDA001N CMS Funding Number: NNH13ZDA001N CMS Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| ROSES 2013 Ocean Salinity Science Team Apply for NNH13ZDA001N OSST Funding Number: NNH13ZDA001N OSST Agency: NASA Headquarters Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Defense Sciences Research and Technology Apply for DARPA BAA 13 20 Funding Number: DARPA BAA 13 20 Agency: DARPA Defense Sciences Office Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Instrument Development for Biological Research Apply for 13 561 Funding Number: 13 561 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 14 DMRDP MID ARA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.